Copenhagen, 2015-03-03 10:32 CET (GLOBE NEWSWIRE) -- Copenhagen, 3 March 2015 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) will announce its Full Year Results and publish the Annual Report for 2014 on Friday, 13 March 2015 in the morning in accordance with the company’s financial calendar.
Conference call – Friday, 13 March 2015 at 14.00 CET/ 09.00 EDT
On the day of release, Zealand’s management will host a conference call at 14.00 CET/ 09:00 EDT to present the Full Year results and Annual Report for 2014. Participating in the call will be Britt Meelby Jensen, President and Chief Executive Officer, Mats Blom, Chief Financial Officer, Torsten Hoffmann, Chief Scientific Officer and Hanne Leth Hillman, Vice President and Head of IR and Corporate Communications. The presentation will be followed by a Q&A session.
The conference call will be conducted in English and the dial-in numbers are:
DK standard access +45 3272 8018
UK and international +44 (0) 1452 555131
US (free dial-in) +1 866 682 8490
A live audio cast of the call including an accompanying slide presentation will be available via the following link, http://edge.media-server.com/m/p/dds2yh7m, accessible also from the Investor section of the company’s website (www.zealandpharma.com). Participants are advised to register for the audio cast approximately 10 minutes before the start.
A replay of the event will be made available from the Investor section of Zealand’s website following the call.
●●●●●
For further information, please contact:
Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a proprietary pipeline of novel medicines alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory filing for Lyxumia® is planned for Q3 2015 and US/EU filings for LixiLan in Q4 2015.
Zealand proprietary pipeline includes danegaptide (prevention of Ischemic Reperfusion Injury) and the stable glucagon product, ZP4207 (treatment of severe hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
